Overall vaccine sales declined by 4% in 2024. Shingrix, GSK’s shingles vaccine, saw a modest 1% increase in sales, while sales for its respiratory syncytial virus (RSV) vaccine Arexvy dropped by 51%.

Following similar deals in countries like the United States and the U.K., Canada is bolstering its stockpile of bird flu ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

MediSave can be used to pay for the cost of the vaccine after subsidies from 2026. Read more at straitstimes.com.

Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) reflecting updated views and recent competitive ...

CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...

Subsidies and existing MediSave schemes could possibly bring the out-of-pocket cost of Shingrix down to zero, says Health ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand ...

Bengaluru: India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by ...